Rashid Waqar, Ciccarelli Olga, Leary Siobhan M, Arun Tarunya, Doshi Anisha, Evangelou Nikos, Ford Helen L, Hobart Jeremy, Jacob Saiju, Muraro Paolo Antonio, Murray Katy, Palace Jacqueline, Dobson Ruth
St George's University Hospitals NHS Foundation Trust, London, UK
NMR Research Unit, Queen Square Multiple Sclerosis Centre, University College London Queen Square Institute of Neurology, London, UK.
Pract Neurol. 2025 Jan 16;25(1):18-24. doi: 10.1136/pn-2024-004228.
The Association of British Neurologists last published guidelines on disease-modifying treatment (DMT) in multiple sclerosis (MS) in 2015. Since then, additional DMTs have been licensed and approved for prescribing within the National Health Service for relapsing-remitting MS, early primary progressive MS and active secondary progressive MS. This updated guidance provides a consensus-based approach to using DMTs. We provide recommendations for eligibility, starting, monitoring, switching and stopping of DMTs; pregnancy; equitable access to DMT; autologous haemopoietic stem-cell transplantation; and use of generics. We highlight best practice where it exists and discuss future priorities.
英国神经学家协会上次发布关于多发性硬化症（MS）疾病修正治疗（DMT）的指南是在2015年。自那时以来，已有更多的DMT药物获得许可并被批准在英国国家医疗服务体系内用于复发缓解型MS、早期原发进展型MS和活动期继发进展型MS的处方。本更新指南提供了一种基于共识的DMT使用方法。我们针对DMT的适用资格、起始、监测、换药和停药；妊娠；公平获得DMT；自体造血干细胞移植；以及仿制药的使用提供了建议。我们突出了现有的最佳实践并讨论了未来的优先事项。
